Phase 1a Study of H1710 Injection to Assess Safety and How It Works in Adults With Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating H1710 for Injection in adults with advanced solid tumors in this phase Ia clinical study. The study aims to assess the safety, tolerability, and how the drug behaves in the body. Participants included have advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants will receive H1710 for Injection according to the study protocol. This single-group trial involves administering the drug and monitoring its effects. The study will track adverse events, dose limiting toxicities, and determine the maximum tolerated dose as well as the recommended dose for future studies over a period of up to 18 months. During the study, participants will undergo evaluations including safety assessments, laboratory tests, and imaging to measure tumor response using RECIST criteria. Researchers will measure drug concentration levels and other pharmacokinetic parameters. The study also monitors disease control, response duration, and progression-free survival. The total participation may last up to approximately 18 months, with regular visits to monitor health and treatment effects.

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors